Table 3 Summary of the genes that were down-regulated by doxorubicin treatment, including the log ratios
Samples with decreased expression (n) | Gene symbol | Mean log ratio | Range of log ratio | Samples with increased expression (n) | Mean log ratio | Range of log ratio |
|---|---|---|---|---|---|---|
11 | CD14 | -2.99 | -0.27/-5.38 | 0 | - | - |
10 | TIA1 | -0.68 | -0.24/-1.05 | 1 | - | 0.77 |
10 | YWHAH | -0.72 | -0.27/-1.80 | 0 | - | - |
10 | PPP3CA | -0.69 | -0.34/-1.14 | 0 | - | - |
10 | ITGB2 | -2.87 | -0.58/-5.11 | 0 | - | - |
9 | PDGFRA | -1.32 | -0.42/-3.30 | 2 | 2.62 | 1.21/4.03 |
9 | RASA1 | -0.93 | -0.42/-1.17 | 0 | - | - |
8 | LDHB | -0.60 | -0.32/-1.25 | 2 | 1.11 | 0.64/1,58 |
8 | CSF1R | -3.05 | -0.63/-5.08 | 0 | - | - |
8 | RARA | -0.95 | -0.51/-1.23 | 0 | - | - |
7 | ANXA4 | -1.10 | -0.64/-1.16 | 4 | 1.37 | 0.84/2.33 |
7 | CTSB | -0.93 | -0.23/-1.97 | 3 | 0.94 | 0.82/1.13 |
7 | DAPK1 | -1.35 | -0.59/-2.07 | 2 | 1,40 | 1.19/1.60 |
7 | CASP1 | -1.69 | -0.71/-2.90 | 2 | 1.44 | 0.97/1.90 |
7 | PRF1 | -1.68 | -0.54/-3.68 | 2 | 0.79 | 0.67/0.91 |
7 | EPHB4 | -1.30 | -0.68/-2.34 | 1 | - | 0.30 |
7 | HCK | -1.79 | -0.39/-3.65 | 1 | - | 1.08 |
7 | ESD | -0.76 | -0.44/-0.95 | 1 | - | 0.36 |
7 | DHCR24 | -1.97 | -0.75/-4.34 | 0 | - | - |
7 | PPP1CB | -0.99 | -0.62/-1.56 | 0 | - | - |
7 | MYO18A/TIAF1 | -1.23 | -0.67/-2.02 | 0 | - | - |
7 | BIRC5 | -2.95 | -1.17/-4.91 | 0 | - | - |
7 | PDGFRB | -1.28 | -0.61/-2.26 | 0 | - | - |
7 | ATG5 | -1.39 | -0.61/-3.19 | 0 | - | - |
7 | DOCK1 | -0.86 | -0.40/-1.23 | 0 | - | - |
7 | PTPN13 | -1.97 | -0.69/-3.17 | 0 | - | - |
7 | BTK | -1.78 | -0.39/-3.28 | 0 | - | - |
7 | SYK | -4.26 | -0.34/-8.06 | 0 | - | - |